Why the study?
Do platelet aggregation and interleukin levels differ between survivors and non-survivors in the acute phases of ischemic stroke?
Do platelet aggregation and interleukin levels differ between survivors and non-survivors in the acute phases of ischemic stroke?
Changes in platelet aggregation and specific interleukin levels correlate with clinical outcomes and survival in the acute phase of ischemic stroke.
May identify high-risk ischemic stroke patients via platelet and interleukin markers; leaves open therapeutic implications requiring prospective trials.
AIM: To compare indicators of platelet aggregation (PA) and the level of interleukins IL-1β, IL-4, IL-6, IL-18 in patients with ischemic stroke (IS). MATERIAL AND METHODS: A prospective clinical cohort study involved 108 IS patients classified into group 1 (survivors) and group 2 (fatal outcomes). The studies were conducted in the most acute and acute phases of IS. The level of interleukins was measured by enzyme immunoassay method. PA was evaluated by the nephelometric method. RESULTS AND CONCLUSION: group showed further increase in IL-1β and IL-6, and reduction of IL-4 levels. In surviving acute IS patients, the reduction in PA and the level of pro-inflammatory interleukins IL-1b, IL-6 and IL-18, and the increase in the level of anti-inflammatory interleukin IL-4 were accompanied with improvements in the clinical condition, whereas the negative dynamics of the aforementioned indicators was recorded in deceased patients.
No takes yet. Share an insight, caveat, or question.
Hovhannisyan et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: